Sep. 04, 2013 | Urology & Urogynecology

LABORIE ACQUIRES UROMED TECHNOLOGY, INC.

LABORIE completed its agreement with UroMed Technology, Inc. to acquire their Pelvic Muscle Rehabilitation business. UroMed Technology, Inc. develops, manufactures and distributes innovative and advanced biofeedback and electrical stimulation equipment, accessories and consumables for pelvic floor dysfunction in the treatment of Urinary and Fecal Incontinence.

“This acquisition strengthens our foundation in Pelvic Muscle Rehabilitation and expands our presence in the conservative therapy sector by offering brands that are synonymous with innovation and quality”, stated Brian Ellacott, President and CEO.   “Both LABORIE and UroMed Technology, Inc. have a shared commitment to helping healthcare professionals deliver better products and services, and to make life more rewarding and dignified for those who use our products.  By combining existing product lines with our extensive customer base, we can provide greater support and commitment to customers worldwide.”

About LABORIE                                                                             

LABORIE (www.laborie.com), headquartered in Toronto, Canada, is a leading global developer, manufacturer and marketer of innovative medical technology and consumables used for the diagnosis and treatment of Urinary and Fecal Incontinence, as well as other pelvic floor disorders in the Urology, Gynecology, and Colorectal fields.

Share This Article

Featured Articles

Completion of Clinical Innovations Acquisition

LABORIE Medical Technologies, a leading diagnostic and therapeutic medical technology company, today announced it has completed its acquisition of Clinical Innovations for an enterprise value of $525 million.

LABORIE to Acquire Clinical Innovations

LABORIE Medical Technologies, a leading global developer and manufacturer of medical diagnostics and devices in the pelvic health and gastroenterology market, today announces the execution of a definitive agreement to acquire Clinical Innovations for an enterprise value of $525 million.

LABORIE MEDICAL TECHNOLOGIES AND COGENTIX MEDICAL ANNOUNCE COMPLETION OF ACQUISITION OF COGENTIX MED

LABORIE Medical Technologies (“LABORIE”) and Cogentix Medical, Inc. (NASDAQ: CGNT) (“Cogentix”) today announced the completion of the acquisition by LABORIE of Cogentix through LABORIE’S affiliate Camden Merger Sub, Inc. (“Merger Sub”), a wholly owned subsidiary of LM US Parent, Inc. (“Parent”).